Health Care·Life Sciences Tools & Services·$9.7B
Revvity Inc is a healthcare company specializing in life sciences tools and services. With a market cap of $11 billion, it plays a crucial role in providing innovative solutions that support research and development in the life sciences sector, which is increasingly focused on advanced technologies and data-driven insights.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
While specific revenue estimates are not available, growth in revenue is essential for sustaining the company's market position and investor confidence.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
Revvity Inc is a healthcare company specializing in life sciences tools and services. With a market cap of $11 billion, it plays a crucial role in providing innovative solutions that support research and development in the life sciences sector, which is increasingly focused on advanced technologies and data-driven insights.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+6.31%
Avg Stock Reaction
+0.53%
In the last quarter, Revvity reported an EPS of $1.70, exceeding expectations by 7.26%. However, the stock experienced a slight decline of 1.57% the following day, indicating mixed investor sentiment despite the earnings beat.
Management Promises & Guidance
Overall, expectations for Revvity's upcoming earnings are cautiously optimistic, given its track record of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.
Bull Case
If Revvity can deliver strong EPS and demonstrate solid revenue growth, it could significantly boost investor confidence and drive the stock higher.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the current market volatility.
Earnings Per Share (EPS)
Expected to be around $1.70.EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue estimates are not available, growth in revenue is essential for sustaining the company's market position and investor confidence.
Operating Margin
N/AThis metric will help assess the efficiency of the company's operations and its ability to convert revenue into profit.
The print will turn on these two things.
Q1
What is the expected EPS for Q1-2026?
EPS is a critical measure of profitability, and any significant deviation from expectations could impact stock performance.
Q2
Will there be any guidance on revenue growth for the upcoming quarters?
Guidance on revenue growth will provide insights into the company's future performance and help investors gauge its market position.
Why consensus could be wrong
The Street may be underestimating Revvity's ability to leverage recent innovations in life sciences tools, which could drive stronger-than-expected revenue growth.
Supporting Evidence
Revvity has consistently beaten EPS estimates, indicating strong operational performance.
The options market is pricing a larger move than historical averages suggest, indicating potential for a surprise.
Recent trends in the life sciences sector show increasing demand for innovative tools, which Revvity is well-positioned to capitalize on.
Key Risk
If Revvity's revenue growth exceeds expectations, it could lead to a significant reevaluation of the stock.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched, especially given the company's history of beating EPS estimates but facing stock price declines post-earnings.
Bull Confirmed If
An EPS of $1.70 or higher with strong revenue growth would confirm the bull case.
Bear Confirmed If
An EPS below $1.60 or weak revenue guidance would support the bear case.
Implied Move
±9.9%
Historical Avg
±3.6%
The options market is pricing in a significant move of nearly 10% around the earnings announcement, indicating heightened volatility expectations.
Options are pricing ±9.9% while RVTY has averaged ±3.6% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Revvity beats expectations and raises guidance, history suggests the stock could rise by an average of 0.53% on the first day.
In-Line / Cautious
If results are in line with expectations but management provides cautious commentary, the stock may see muted movement.
Miss
If Revvity misses EPS expectations, history suggests a potential decline of around 3.58% on the first day.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026